deuterated psilocybin

Deuterated psilocybin (LNH-007) is a small molecule drug candidate being developed by Lennham Pharmaceuticals for the treatment of Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). It is a deuterated analogue of psilocybin, a naturally occurring psychedelic prodrug. The incorporation of deuterium into the molecular structure is intended to improve the drug's pharmacokinetic profile by enhancing metabolic stability and potentially reducing patient-to-patient variability in drug exposure. Like its non-deuterated counterpart, it acts as a prodrug for psilocin (or its deuterated form), which is a potent agonist at the serotonin 5-HT2A receptor. Activation of this receptor is associated with increased neuroplasticity and the facilitation of therapeutic psychological insights, which are believed to underlie its efficacy in treating chronic psychiatric conditions.

Other names

d-psilocybindeuterated psilocybin